Astrazeneca is part of the healthcare sector and is in the drug manufacturers industry. The company CEO is Pascal Soriot. AstraZeneca belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.
Previous Intraday Performance:
The AZN shares had a previous change of -0.80% which opened at 39.63 and closed at 39.52. It moved to an intraday high of 40.02 and a low of 39.47.
Over the last five trading days, AZN shares returned -3.28% and in the past 30 trading days it returned -5.21%. Over three months, it changed 11.95%. In one year it has changed 14.39% and within that year its 52-week high was 43.30 and its 52-week low was 34.38. AZN stock is 14.95% above its 52 Week Low.
Our calculations result in a 200 day moving average of 37.97 and a 50 day moving average of 40.43. Right now, AZN stock is trading 4.09% above its 200 day moving average and may be a good opportunity to buy.
The company has a market cap of $103.7b with 2.6b shares outstanding and a float of 2.6b shares. Trading volume was 8,235,832 shares and has experienced an average volume of 5,761,086 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.
The last annual reported EPS for Astrazeneca was 0.85 which ended on 31st of December 2018, which according to the previous close, that is a PE of 46.49. Based on 3 analyst estimates, the consensus EPS for the next quarter is 0.42. The trailing twelve month EPS is 3.46, which comes to a trailing twelve month PE of 11.42. Historically, the PE high was 74.90 and the PE low was 11.42. AZN stock has set a new PE low record!
The dividend per share is currently 1.90, which is a dividend yield of 4.81%. Also, the payout ratio is 54.91%, therefore the dividend is safe according to our calculations. AZN stock has a high dividend yield, but because the company has enough earnings to cover future dividends, it might be a good investment opportunity for an income portfolio.
Base on our calculations, the intrinsic value per share is 71.89, which means it might be undervalued and has a margin of safety of 45.03%
The next earnings report will be: 04-26-2019
The long-term trend of the EPS is a vital number as it helps understand the future potential of Astrazeneca; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which is 10.15%.
Indicators Also to Watch:
Based on the latest filings, there is 27.40% of institutional ownership. Short-interest was 16,761,979, which was 0.64% of shares outstanding. The short-interest ratio or days-to-cover ratio was 3.07. This stock has some short interest, but it might be normal and no need to worry if long the position.
I calculated the beta to be 0.51
Based on last reported financials, the company’s return on equity is 15.71%, return on assets is 3.48%, profit margin is 10.25%, price-to-sales is 0.08 and price-to-book is 8.56.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
0 : Financial Safety Result
1 : Past Performance Result
2 : Valuation Result
4 : Dividend Safety Result
2 : Overall Result